期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 6, 期 4, 页码 543-550出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.30
关键词
biological therapy; Crohn's disease; drug delivery/targeting; gene therapy/delivery; inflammatory bowel disease; microcarriers; molecular biopharmaceutics; nanocarriers; transgenic bacteria; ulcerative colitis
类别
The therapeutic management of inflammatory bowel disease (IBD) represents the perfect scenario for drug targeting to the site(s) of action. While existing formulation-based targeting strategies include rectal dosage forms and oral systems that target the colon by pH-, time-, microflora- and pressure-triggered drug release, novel approaches for site-specific delivery in IBD therapy will target the inflamed intestine per se rather than intestinal region. The purpose of this article is to present a mechanistic update on the strategies employed to achieve minimal systemic exposure accompanied by maximal drug levels in the inflamed intestinal tissue. The introduction of biological agents, micro/nanoparticulate carriers including liposomes, transgenic bacteria, and gene therapy opportunities are discussed, as well as the challenges remaining to be achieved in the targeted treatment of IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据